Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
51
AMPH Quote, Financials, Valuation and Earnings
Last price:
$28.51
Seasonality move
:
3.24%
Day range:
$28.03 - $28.98
52-week range:
$20.39 - $32.69
Dividend yield:
0%
P/E ratio:
12.65x
P/S ratio:
1.94x
P/B ratio:
1.69x
Volume:
508.4K
Avg. volume:
328.9K
1-year change:
-8.85%
Market cap:
$1.3B
Revenue:
$732M
EPS (TTM):
$2.26
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$190.1M | $0.92 | 1.61% | 56.77% | $31.57 |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$142.8M | $0.50 | 1.73% | 35.24% | $34.57 |
|
CRMD
CorMedix, Inc.
|
$127M | $0.81 | 178.58% | 96.01% | $14.86 |
|
LLY
Eli Lilly & Co.
|
$17.9B | $6.91 | 36.93% | 135.67% | $1,211.21 |
|
OGN
Organon & Co.
|
$1.5B | $0.73 | -1.13% | 131.6% | $9.21 |
|
PFE
Pfizer Inc.
|
$16.8B | $0.57 | 1.25% | 39.81% | $28.56 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$28.53 | $31.57 | $1.3B | 12.65x | $0.00 | 0% | 1.94x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$24.30 | $34.57 | $3B | 14.18x | $0.00 | 0% | 5.34x |
|
CRMD
CorMedix, Inc.
|
$7.03 | $14.86 | $553.9M | 3.42x | $0.00 | 0% | 2.37x |
|
LLY
Eli Lilly & Co.
|
$1,009.52 | $1,211.21 | $952.3B | 44.69x | $1.73 | 0.62% | 14.11x |
|
OGN
Organon & Co.
|
$8.10 | $9.21 | $2.1B | 11.30x | $0.02 | 4.2% | 0.34x |
|
PFE
Pfizer Inc.
|
$26.65 | $28.56 | $151.5B | 19.67x | $0.43 | 6.45% | 2.43x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
45.82% | 0.342 | 53.17% | 2.07x |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
0.31% | -0.890 | 0.12% | 6.19x |
|
CRMD
CorMedix, Inc.
|
1.16% | 2.679 | 0.48% | 1.60x |
|
LLY
Eli Lilly & Co.
|
62.31% | -0.536 | 4.56% | 0.71x |
|
OGN
Organon & Co.
|
90.69% | -0.940 | 463.5% | 0.81x |
|
PFE
Pfizer Inc.
|
39.94% | 0.402 | -- | 0.81x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
$95M | $25.3M | 7.98% | 14.9% | 13.2% | $47.2M |
|
CPRX
Catalyst Pharmaceuticals, Inc.
|
$116.4M | $66.3M | 27.37% | 27.48% | 44.66% | $32.4M |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
LLY
Eli Lilly & Co.
|
$15.9B | $9B | 34.71% | 104.39% | 46.58% | $254.2M |
|
OGN
Organon & Co.
|
$741M | $217M | 1.95% | 79.63% | 14.4% | $149M |
|
PFE
Pfizer Inc.
|
$12.3B | $3.7B | 5.07% | 10.84% | 21.01% | $4B |
Amphastar Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns AMPH or CPRX?
Catalyst Pharmaceuticals, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 35.57%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 27.48%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B CPRXCatalyst Pharmaceuticals, Inc.78.44% $0.42 $923.1M -
What do Analysts Say About AMPH or CPRX?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.57, signalling upside risk potential of 10.66%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.57 which suggests that it could grow by 42.27%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 CPRXCatalyst Pharmaceuticals, Inc.7 0 0 -
Is AMPH or CPRX More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.876, which suggesting that the stock is 12.394% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.735, suggesting its less volatile than the S&P 500 by 26.455%.
-
Which is a Better Dividend Stock AMPH or CPRX?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or CPRX?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than Catalyst Pharmaceuticals, Inc. quarterly revenues of $148.4M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.8M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.65x while Catalyst Pharmaceuticals, Inc.'s PE ratio is 14.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.94x versus 5.34x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.94x 12.65x $191.8M $17.4M CPRXCatalyst Pharmaceuticals, Inc.5.34x 14.18x $148.4M $52.8M
-
Which has Higher Returns AMPH or CRMD?
CorMedix, Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 49.9%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.57, signalling upside risk potential of 10.66%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.86 which suggests that it could grow by 111.34%. Given that CorMedix, Inc. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe CorMedix, Inc. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 CRMDCorMedix, Inc.4 0 0 -
Is AMPH or CRMD More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.876, which suggesting that the stock is 12.394% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.388, suggesting its more volatile than the S&P 500 by 38.76%.
-
Which is a Better Dividend Stock AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or CRMD?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.65x while CorMedix, Inc.'s PE ratio is 3.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.94x versus 2.37x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.94x 12.65x $191.8M $17.4M CRMDCorMedix, Inc.2.37x 3.42x $104.3M $108.6M
-
Which has Higher Returns AMPH or LLY?
Eli Lilly & Co. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of 34.4%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Eli Lilly & Co.'s return on equity of 104.39%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B LLYEli Lilly & Co.82.52% $7.02 $70.4B -
What do Analysts Say About AMPH or LLY?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.57, signalling upside risk potential of 10.66%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,211.21 which suggests that it could grow by 19.98%. Given that Eli Lilly & Co. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Eli Lilly & Co. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 LLYEli Lilly & Co.18 6 0 -
Is AMPH or LLY More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.876, which suggesting that the stock is 12.394% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.388, suggesting its less volatile than the S&P 500 by 61.171%.
-
Which is a Better Dividend Stock AMPH or LLY?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.62% to investors and pays a quarterly dividend of $1.73 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AMPH or LLY?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.65x while Eli Lilly & Co.'s PE ratio is 44.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.94x versus 14.11x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.94x 12.65x $191.8M $17.4M LLYEli Lilly & Co.14.11x 44.69x $19.3B $6.6B
-
Which has Higher Returns AMPH or OGN?
Organon & Co. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -13.6%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Organon & Co.'s return on equity of 79.63%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B OGNOrganon & Co.49.17% -$0.79 $9.7B -
What do Analysts Say About AMPH or OGN?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.57, signalling upside risk potential of 10.66%. On the other hand Organon & Co. has an analysts' consensus of $9.21 which suggests that it could grow by 13.76%. Given that Organon & Co. has higher upside potential than Amphastar Pharmaceuticals, Inc., analysts believe Organon & Co. is more attractive than Amphastar Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 OGNOrganon & Co.0 3 0 -
Is AMPH or OGN More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.876, which suggesting that the stock is 12.394% less volatile than S&P 500. In comparison Organon & Co. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock AMPH or OGN?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Organon & Co. offers a yield of 4.2% to investors and pays a quarterly dividend of $0.02 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Organon & Co. pays out 47.22% of its earnings as a dividend. Organon & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios AMPH or OGN?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Organon & Co. quarterly revenues of $1.5B. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Organon & Co.'s net income of -$205M. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.65x while Organon & Co.'s PE ratio is 11.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.94x versus 0.34x for Organon & Co.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.94x 12.65x $191.8M $17.4M OGNOrganon & Co.0.34x 11.30x $1.5B -$205M
-
Which has Higher Returns AMPH or PFE?
Pfizer Inc. has a net margin of 9.04% compared to Amphastar Pharmaceuticals, Inc.'s net margin of -9.34%. Amphastar Pharmaceuticals, Inc.'s return on equity of 14.9% beat Pfizer Inc.'s return on equity of 10.84%.
Company Gross Margin Earnings Per Share Invested Capital AMPHAmphastar Pharmaceuticals, Inc.49.53% $0.36 $1.4B PFEPfizer Inc.69.97% -$0.29 $154.8B -
What do Analysts Say About AMPH or PFE?
Amphastar Pharmaceuticals, Inc. has a consensus price target of $31.57, signalling upside risk potential of 10.66%. On the other hand Pfizer Inc. has an analysts' consensus of $28.56 which suggests that it could grow by 7.18%. Given that Amphastar Pharmaceuticals, Inc. has higher upside potential than Pfizer Inc., analysts believe Amphastar Pharmaceuticals, Inc. is more attractive than Pfizer Inc..
Company Buy Ratings Hold Ratings Sell Ratings AMPHAmphastar Pharmaceuticals, Inc.2 4 0 PFEPfizer Inc.7 16 1 -
Is AMPH or PFE More Risky?
Amphastar Pharmaceuticals, Inc. has a beta of 0.876, which suggesting that the stock is 12.394% less volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.
-
Which is a Better Dividend Stock AMPH or PFE?
Amphastar Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.45% to investors and pays a quarterly dividend of $0.43 per share. Amphastar Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.
-
Which has Better Financial Ratios AMPH or PFE?
Amphastar Pharmaceuticals, Inc. quarterly revenues are $191.8M, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. Amphastar Pharmaceuticals, Inc.'s net income of $17.4M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, Amphastar Pharmaceuticals, Inc.'s price-to-earnings ratio is 12.65x while Pfizer Inc.'s PE ratio is 19.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amphastar Pharmaceuticals, Inc. is 1.94x versus 2.43x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income AMPHAmphastar Pharmaceuticals, Inc.1.94x 12.65x $191.8M $17.4M PFEPfizer Inc.2.43x 19.67x $17.6B -$1.6B
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
77
RNG alert for Feb 21
RingCentral, Inc. [RNG] is up 34.37% over the past day.
Sell
9
FROG alert for Feb 21
JFrog Ltd. [FROG] is down 24.98% over the past day.
Buy
72
SNSE alert for Feb 21
Sensei Biotherapeutics, Inc. [SNSE] is up 23.81% over the past day.
